Complications revision fusions re-admissions and utilization over a one-year period following bone morphogenetic protein use during primary cervical spine fusions

摘要

BackgroundNationwide estimates examining Bone Morphogenetic Protein (BMP) use with cervical spine fusions have been limited to perioperative outcomes.